About
ADC (Antibody-Drug Conjugate), Anti-biotics, Anti-coagulants & Anti-cancer therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibody
Clinical Trials (15)
View allTotal Trials
15
As Lead Sponsor
13
As Collaborator
2
Total Enrollment
1,277
By Phase
PHASE1: 9PHASE2: 5PHASE1/PHASE2: 1
By Status
COMPLETED: 9RECRUITING: 3TERMINATED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06774963Collaborator
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
PHASE1Recruiting
145 participants
Started: Jan 7, 2025 · Completed: Dec 31, 2026
NCT06004037Lead Sponsor
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
PHASE2Active, not recruiting
20 participants
Started: Jan 16, 2024 · Completed: Dec 30, 2026
NCT05941507Lead Sponsor
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
PHASE1/PHASE2Recruiting
300 participants
Started: Oct 5, 2023 · Completed: May 31, 2027
NCT05807399Collaborator
PanACEA - STEP2C -01
PHASE2Recruiting
390 participants
Started: Apr 14, 2023 · Completed: Dec 30, 2027
NCT05225558Lead Sponsor
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
PHASE2Terminated
40 participants
Started: Apr 26, 2022 · Completed: Mar 18, 2024
Locations (1)
Headquarters
Daejeon, Korea
Map
Loading map...